Contents hide 1 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 2 Mantle Cell Lymphoma 3 Waldenström Macroglobulinemia 4 Marginal Zone Lymphoma 5 Chronic Graft vs Host Disease 6 Dosage Modifications 6.1 Grade 2 cardiac failure 6.1.1 MCL and MZL 6.1.2 CLL/SLL, WM, and cGVHD 6.2 Grade 3 cardiac arrhythmias 6.2.1 MCL and MZL 6.2.2 CLL/SLL, WM, and cGVHD 6.3 Grade ≥3 cardiac failure or Grade 4 cardiac arrhythmias 6.4 Nonhematological and hematologic toxicities 6.4.1 MCL and MZL 6.4.2 CLL/SLL, WM, and cGVHD 6.5 Coadministration with CYP3A inhibitors 6.5.1 Reduce ibrutinib dose to 280 mg qDay when coadministered with the following 6.5.2 Reduce … Continue reading ILUDX (Ibrutinib)